{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:37:17Z","timestamp":1793090237281,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105592","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:32:00Z","timestamp":1789666320000},"page":"105592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From ICI resistance to therapeutic vulnerability: A resistance-state framework for appraising antibody\u2013drug conjugate evidence in solid tumors"],"prefix":"10.1016","volume":"227","author":[{"given":"Yaoyao","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105592_bib1","article-title":"Optimizing wound healing with antibacterial metal oxide nanoparticles: a comparative analysis of efficacy and biological mechanisms","volume":"105","author":"Abbas","year":"2025","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1535-7163.MCT-25-0101","article-title":"PF-08046032: a novel, investigational CD25-directed antibody-drug conjugate optimized for selective depletion of regulatory T cells in advanced malignant tumors","volume":"24","author":"Abdelhamed","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105592_bib3","doi-asserted-by":"crossref","DOI":"10.1063\/5.0092330","article-title":"Nanoformulation of intelligence polymeric nanocarrier for resveratrol targeted delivery and study its cytotoxic, apoptotic, and genetics effects in epidermoid carcinoma therapy","volume":"2437","author":"Alnasraui","year":"2022","journal-title":"AIP Conf. Proc."},{"key":"10.1016\/j.critrevonc.2026.105592_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"10.1016\/j.critrevonc.2026.105592_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1565859","article-title":"Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells","volume":"8","author":"Bauzon","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105592_bib6","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","article-title":"Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade","volume":"81","author":"Boshuizen","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105592_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell. Metab."},{"key":"10.1016\/j.critrevonc.2026.105592_bib8","article-title":"A Phase 1b study of telisotuzumab vedotin in combination with nivolumab in patients with NSCLC","volume":"3","author":"Camidge","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.critrevonc.2026.105592_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors","volume":"22","author":"Catanzaro","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12967-025-06434-1","article-title":"LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth","volume":"23","author":"Cela","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105592_bib11","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-25-0682","article-title":"Immune reprogramming of tumor microenvironments by cytotoxic antibody-drug conjugate payloads","volume":"25","author":"Chakravorty","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105592_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D\u2019Amico","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105592_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105592_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105592_bib15","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","article-title":"OMTX705, a Novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models","volume":"26","author":"Fabre","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105592_bib16","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105592_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2514050","article-title":"Patritumab deruxtecan induces immunogenic cell death","volume":"14","author":"Forveille","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105592_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105592_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.06.012","article-title":"SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive\/HER2-negative breast cancer","author":"Garrido-Castro","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib20","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA Class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105592_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007572","article-title":"SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models","volume":"11","author":"Gray","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105592_bib22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12668-025-02144-6","article-title":"Superparamagnetic iron oxide nanoparticles: multifunctional targeted platforms for cancer detection and combination therapy","volume":"15","author":"Haider","year":"2025","journal-title":"BioNanoScience"},{"key":"10.1016\/j.critrevonc.2026.105592_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.06.003","article-title":"Becotatug vedotin for recurrent\/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial","author":"Han","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1172\/JCI126598","article-title":"U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation","volume":"130","author":"Haratani","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105592_bib26","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.annonc.2025.05.010","article-title":"Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis","volume":"36","author":"Hoffman-Censits","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib27","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-extra domain b splice variant of fibronectin antibody-drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105592_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","article-title":"A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+\u2009tumors in hPD-1 transgenic mouse model and contributes immune memory formation","volume":"191","author":"Huang","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105592_bib29","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105592_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105592_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105592_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1158\/1535-7163.MCT-24-0444","article-title":"Broad-spectrum efficacy of CEACAM6-targeted antibody-drug conjugate with BET protein degrader in colorectal, lung, and breast cancer mouse models","volume":"24","author":"Kogai","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105592_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1158\/1078-0432.CCR-24-1478","article-title":"Phase II open-label trial of brentuximab vedotin with pembrolizumab in PD-1-pretreated metastatic non-small cell lung cancer and metastatic cutaneous melanoma","volume":"31","author":"Lee","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105592_bib35","first-page":"175","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.critrevonc.2026.105592_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","article-title":"Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors","volume":"25","author":"Lv","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105592_bib38","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jtho.2021.02.022","article-title":"A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC","volume":"16","author":"Malhotra","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107928","article-title":"Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma","volume":"195","author":"Mansfield","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105592_bib40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105592_bib41","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses In vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105592_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105592_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115603","article-title":"Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1\/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study","volume":"227","author":"Muro","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105592_bib44","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers16152648","volume":"16","author":"Nakane","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105592_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105592_bib46","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib47","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2024.12.044","article-title":"Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1\/PD-L1 blockade therapy-resistant tumor","volume":"33","author":"Oh","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105592_bib48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105592_bib49","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105592_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.12.006","article-title":"Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy","volume":"44","author":"Qu","year":"2026","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104472","article-title":"Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting","volume":"202","author":"Ranganathan","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib52","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105592_bib53","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105592_bib54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105592_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-26-00640","article-title":"Becotatug vedotin combined with pucotenlimab in platinum- and immunotherapy-resistant recurrent or metastatic nasopharyngeal carcinoma","author":"Ruan","year":"2026","journal-title":"J. Clin. Oncol. JCO-26-00640."},{"key":"10.1016\/j.critrevonc.2026.105592_bib56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105592_bib57","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105592_bib58","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105592_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105592_bib60","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1007\/s11468-024-02469-0","article-title":"Laser-fabricated metal oxide core-shell nanoparticles for biomedical applications: a mini review","volume":"20","author":"Talib","year":"2025","journal-title":"Plasmonics"},{"key":"10.1016\/j.critrevonc.2026.105592_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2220466","article-title":"A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells","volume":"15","author":"Tan","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.critrevonc.2026.105592_bib62","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105592_bib63","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib64","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/1535-7163.MCT-22-0786","article-title":"Discovery and preclinical characterization of XMT-1660, an optimized B7-H4-targeted antibody-drug conjugate for the treatment of cancer","volume":"22","author":"Toader","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105592_bib65","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105592_bib66","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102847","article-title":"Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis","volume":"131","author":"Villacampa","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105592_bib68","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1038\/s41388-025-03567-x","article-title":"A novel FAP-targeting antibody-exatecan conjugate improves immune checkpoint blockade by reversing immunosuppressive microenvironment in pancreatic cancer","volume":"44","author":"Wei","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105592_bib69","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.chembiol.2021.02.013","article-title":"HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells","volume":"28","author":"Xia","year":"2021","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.critrevonc.2026.105592_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011881","article-title":"Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48","volume":"13","author":"Xiao","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105592_bib71","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(26)00968-2","article-title":"Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial","volume":"407","author":"Xiong","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105592_bib72","first-page":"262","article-title":"Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.critrevonc.2026.105592_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000860","article-title":"CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity","volume":"8","author":"Zammarchi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105592_bib74","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105592_bib75","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3892\/or.2025.8956","article-title":"Breaking therapeutic barriers in solid tumors: clinical progress of antibody-drug conjugate\/immune checkpoint inhibitor combinations (Review)","volume":"54","author":"Zheng","year":"2025","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105592_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101100","article-title":"Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab","volume":"15","author":"Zhou","year":"2025","journal-title":"J. Pharm. Anal."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:02:11Z","timestamp":1793088131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":76,"alternative-id":["S1040842826004798"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105592","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From ICI resistance to therapeutic vulnerability: A resistance-state framework for appraising antibody\u2013drug conjugate evidence in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105592"}}